GoodRx (NASDAQ:GDRX) Stock Price Down 2.6%

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s stock price fell 2.6% during trading on Friday . The company traded as low as $7.92 and last traded at $8.00. 126,765 shares were traded during mid-day trading, a decline of 91% from the average session volume of 1,475,841 shares. The stock had previously closed at $8.21.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on GDRX. Citigroup lowered their price target on GoodRx from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Barclays increased their target price on GoodRx from $9.00 to $10.00 and gave the company an “overweight” rating in a report on Monday, May 20th. TD Cowen boosted their price target on GoodRx from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, May 16th. UBS Group lowered their price objective on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research note on Friday, August 9th. Finally, Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price for the company in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GoodRx has an average rating of “Moderate Buy” and a consensus price target of $9.36.

GoodRx Stock Down 3.8 %

The stock has a market capitalization of $2.96 billion, a P/E ratio of -790.00, a P/E/G ratio of 4.08 and a beta of 1.39. The company has a debt-to-equity ratio of 1.02, a quick ratio of 6.29 and a current ratio of 6.29. The company’s 50-day moving average price is $8.03 and its 200 day moving average price is $7.52.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $200.60 million during the quarter, compared to analysts’ expectations of $200.47 million. GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.02 earnings per share. As a group, equities analysts expect that GoodRx Holdings, Inc. will post 0.17 earnings per share for the current year.

Hedge Funds Weigh In On GoodRx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cornercap Investment Counsel Inc. boosted its position in shares of GoodRx by 1.7% during the 2nd quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock valued at $587,000 after acquiring an additional 1,266 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of GoodRx by 5.1% in the 1st quarter. California State Teachers Retirement System now owns 70,912 shares of the company’s stock worth $503,000 after buying an additional 3,444 shares during the last quarter. US Bancorp DE raised its position in shares of GoodRx by 3.7% during the 1st quarter. US Bancorp DE now owns 109,818 shares of the company’s stock valued at $780,000 after buying an additional 3,877 shares in the last quarter. Beacon Capital Management LLC bought a new position in shares of GoodRx in the 1st quarter valued at about $28,000. Finally, Plato Investment Management Ltd purchased a new position in GoodRx in the second quarter worth about $43,000. 63.77% of the stock is owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.